INTRODUCTION {#s1}
============

Renal cell carcinoma (RCC) is one of the most common cancers of the human urinary system. Based on cancer statistics, approximately 62,700 new cases will be reported in clinics, with approximately 14,240 deaths in the USA in 2016 \[[@R1]\]. Clear cell renal cell carcinoma (ccRCC) is the most common histological type of RCC, accounting for 70% to 75% of all RCCs \[[@R2]\]. Most patients with RCC are symptom-free in the early stage, and more than 50% of RCCs are found coincidentally by physical examination and imaging \[[@R3]\]. Approximately 30% of the patients with RCC have developed metastases, and the average 5-year survival rate is just 12.3% \[[@R4]\].

Epigenetic and genetic changes are identified to be significantly associated with cancer \[[@R5], [@R6]\]. DNA methylation is an important mechanism of epigenetic alterations involved in gene expression, which is closely associated with the carcinogenesis and progression of various carcinomas \[[@R7]--[@R9]\]. The transcription repression of the gene via CpG island methylation of the promoter can lead to the downregulation of gene expression \[[@R10], [@R11]\]. Located at chromosome 9p21, cyclin-dependent kinase inhibitor 2A (*CDKN2A*) has two alternative splicings, encoding the cell cycle regulatory proteins *p16^INK4A^* and *p14^ARF^*, which have a key function in regulating the activities of the retinoblastoma (RB) and p53 genes, respectively \[[@R12], [@R13]\]. *p16^INK4A^* and *p14^ARF^* as tumor suppressor genes are involved in the regulation of cell division and apoptosis, and the maintenance of cellular homeostasis \[[@R14]\]. The inactivation of *p16^INK4A^* and *p14^ARF^* through promoter methylation has been reported in many cancers \[[@R15]--[@R17]\]. Promoter methylation of *p16^INK4A^* and *p14^ARF^* has been shown in different sample types of RCC, including blood, urine, and tissue samples \[[@R18]--[@R21]\].

Although some studies involving *p16^INK4A^* and *p14^ARF^* promoter methylation included patients with RCC, the studies published in this field have had small sample sizes. In addition, whether *p16^INK4A^* and *p14^ARF^* promoter methylation is associated with clinical characteristics of RCC remains to be determined. Therefore, in this study, we performed a systematic meta-analysis to further evaluate the clinical significance of *p16^INK4A^* and *p14^ARF^* promoter methylation in RCC.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

One hundred sixty-six potentially relevant studies were identified by the initial literature search. According to the inclusion criteria, a total of 14 studies involving 1231 RCC patients and 689 control patients \[[@R18]--[@R31]\] were included in the current analysis (Figure [1](#F1){ref-type="fig"}). Of these studies, which involved *p16^INK4A^* and *p14^ARF^* gene promoter methylation, nine studies evaluated the association between *p16^INK4A^* promoter methylation and RCC risk, five studies assessed the correlation between *p14^ARF^* promoter methylation and RCC risk, ten studies evaluated the relation between *p16^INK4A^* promoter methylation and clinicopathological features, and four studies evaluated the relation between *p14^ARF^* promoter methylation and clinicopathological features. The general characteristics of included studies are presented in Table [1](#T1){ref-type="table"}.

![Flow chart of study selection](oncotarget-08-64385-g001){#F1}

###### General characteristics of all eligible studies

  First author                 Country   Ethnicity    Method   Sample   Cancer   Control   OS     DFS   Gene        
  ---------------------------- --------- ------------ -------- -------- -------- --------- ------ ----- ------ ---- -------
  Kawada 2000 \[[@R30]\]       Japan     Asians       MSP      Tissue   2.2      91        \-     \-    \-     \-   *P14*
  Esteller 2001 \[[@R31]\]     USA       Caucasians   MSP      Tissue   13.1     38        0      38    \-     \-   *P14*
  Battagli 2003 \[[@R26]\]     USA       Caucasians   MSP      Tissue   18       50        0      27    \-     \-   *P14*
  Battagli 2003 \[[@R26]\]     USA       Caucasians   MSP      Urine    18       50        0      12    \-     \-   *P14*
  Dulaimi 2004 \[[@R25]\]      USA       Caucasians   MSP      Tissue   17       100       0      15    NS     \-   *P14*
  Hoque 2004 \[[@R21]\]        USA       Caucasians   QMSP     Urine    30.8     26        0      91    \-     \-   *P14*
  Hoque 2004 \[[@R21]\]        USA       Caucasians   QMSP     Serum    5.55     18        3.33   30    \-     \-   *P14*
  Hori 2007 \[[@R20]\]         Japan     Asians       MSP      Tissue   70.5     44        \-     \-    \-     \-   *P14*
  Hauser 2013 \[[@R18]\]       Germany   Caucasians   \*       Serum    14.3     35        0      54    \-     \-   *P14*
  Kawada 2000 \[[@R30]\]       Japan     Asians       MSP      Tissue   3.3      91        \-     \-    \-     \-   *P16*
  Romanenko 2002 \[[@R29]\]    Spain     Caucasians   MSP      Tissue   31.8     22        \-     \-    \-     \-   *P16*
  Morris 2003 \[[@R27]\]       UK        Caucasians   MSP      Tissue   0        17        0      14    \-     \-   *P16*
  Sanz-Casla 2003 \[[@R28]\]   Spain     Caucasians   PCR      Tissue   20       40        \-     \-    \-     \-   *P16*
  Battagli 2003 \[[@R26]\]     USA       Caucasians   MSP      Tissue   10       50        0      27    \-     \-   *P16*
  Battagli 2003 \[[@R26]\]     USA       Caucasians   MSP      Urine    8        50        0      12    \-     \-   *P16*
  Dulaimi 2004 \[[@R25]\]      USA       Caucasians   MSP      Tissue   10       100       0      15    NS     \-   *P16*
  Hoque 2004 \[[@R21]\]        USA       Caucasians   QMSP     Urine    34.6     26        0      91    \-     \-   *P16*
  Hoque 2004 \[[@R21]\]        USA       Caucasians   QMSP     Serum    22.2     18        0      30    \-     \-   *P16*
  Arai 2006 \[[@R24]\]         Japan     Asians       MSP      Tissue   73.3     60        37     67    \-     \-   *P16*
  Hori 2007 \[[@R20]\]         Japan     Asians       MSP      Tissue   6.8      44        \-     \-    \-     \-   *P16*
  Vidaurreta 2008 \[[@R23]\]   Spain     Caucasians   MSP      Tissue   22.9     48        0      48    NS     NS   *P16*
  Onay 2009 \[[@R19]\]         Turkey    Caucasians   MSP      Tissue   57.1     21        52.4   21    \-     \-   *P16*
  Martino 2012 \[[@R22]\]      Austria   Caucasians   qPCR     Serum    46.5     157       44.2   43    \-     NS   *P16*
  Hauser 2013 \[[@R18]\]       Germany   Caucasians   \*       Serum    25.7     35        16.7   54    \-     \-   *P16*

"\*" Denotes detection method using methylation-sensitive real-time polymerase chain reaction; "-" indicates data not available; MSP: methylation specific polymerase chain reaction; PCR: polymerase chain reaction; qPCR: quantitative polymerase chain reaction; QMSP: quantitative methylation-specific polymerase chain reaction; M: methylation; OS: overall survival; DFS: disease-free survival; NS: not significant.

Association between *p16^INK4A^* and *p14^ARF^* promoter methylation and RCC risk {#s2_2}
---------------------------------------------------------------------------------

When cancer patients were compared to control subjects, the result of *p16^INK4A^* promoter methylation with strong heterogeneity was conducted using a random-effects model (I^2^ = 51.7% and p = 0.029); under a fixed-effects model, no obvious heterogeneity was found for *p14^ARF^* promoter methylation (I^2^ = 0.0%; and p = 0.667) (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}).
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A significant association was found between *p16^INK4A^* promoter methylation and RCC (OR = 2.77, 95% CI = 1.36 - 5.66, P = 0.005), including in 582 of the cancer patients and 422 of the controls (Figure [2](#F2){ref-type="fig"}). The pooled OR of *p14^ARF^* promoter methylation in RCCs was significantly higher than in controls (OR = 11.73, 95% CI = 4.11 - 33.47, P \< 0.001), including in 317 of the cancer patients and 267 of the controls (Figure [3](#F3){ref-type="fig"}).

Subgroup analyses of *p16^INK4A^* promoter methylation in cancer patients versus control patients {#s2_3}
-------------------------------------------------------------------------------------------------

According to sample type (tissue, serum, or urine), ethnicity (Caucasian or Asian), and testing method \[methylation-specific polymerase chain reaction (MSP) and non-MSP\], subgroup analyses were performed for *p16^INK4A^* promoter methylation with significant heterogeneity (Table [2](#T2){ref-type="table"}).

###### The pooled OR of *p16^INK4A^* and *p14^ARF^* promoter methylation and RCC

                          Studies   Overall OR (95 CI %)    I^2^; P        P value    Cases   Controls   P (Egger test)
  ----------------------- --------- ----------------------- -------------- ---------- ------- ---------- ----------------
  *p16INK4A*              9         2.77 (1.36 - 5.66)      51.7%; 0.029   0.005      582     422        0.011
  *p14ARF*                5         11.73 (4.11 - 33.47)    0.0%; 0.667    \< 0.001   317     267        0.193
  Subgroup (*p16INK4A*)                                                                                  
  Ethnicity                                                                                              
  Asians                  1         2.23 (1.06 - 4.71)      NA; NA         0.036      60      67         
  Caucasians              8         3.40 (1.35 - 8.59)      57.6%; 0.016   0.009      522     355        
  Sample                                                                                                 
  Tissue                  6         2.82 (1.61 - 4.95)      22.9%; 0.269   \< 0.001   296     192        
  Serum                   3         1.66 (0.66 - 4.16)      45.1%; 0.162   0.28       210     127        
  Urine                   2         15.82 (0.41 - 608.03)   67.6%; 0.079   0.138      76      103        
  Method                                                                                                 
  MSP                     5         2.06 (1.14 - 3.75)      0.0%; 0.815    0.017      298     156        
  Non-MSP                 4         5.85 (1.28 - 26.77)     77.2%; 0.002   0.023      284     266        

MSP: methylation-specific polymerase chain reaction; NA: not applicable; OR: odds ratio; 95% confidence interval (95% CI).

Subgroup analyses based on sample types showed that *p16^INK4A^* promoter methylation was significantly associated with RCC risk in tissue (OR = 2.82, 95% CI = 1.61-4.95, P \< 0.001), but not in serum or urine (OR = 1.66, 95% CI = 0.66-4.16, P = 0.28; OR = 15.82, 95% CI = 0.41-608.03, P = 0.138, respectively). Subgroup analyses based on ethnicity and testing methods suggested that *p16^INK4A^* promoter methylation was significantly correlated with RCC risk in different ethnicities and by different testing methods (all P \< 0.05).

Meta regression and sensitivity analyses of *p16^INK4A^* promoter methylation in cancer patients versus control patients {#s2_4}
------------------------------------------------------------------------------------------------------------------------

Meta regression based on sample type (tissue, serum, or urine), ethnicity (Caucasian or Asian), and testing method (MSP or non-MSP) was performed to find the potential sources of heterogeneity (Table [3](#T3){ref-type="table"}).

###### Meta regression analysis of *p16^INK4A^* promoter methylation

  Subgroup          Coefficient (95% CI)      t       P value
  ----------------- ------------------------- ------- ---------
  Testing method    2.835 (−0.681, 6.352)     1.97    0.096
  Ethnicity         −0.225 (−2.909, 2.459)    −0.20   0.845
  Sample material   −1.521 (−3.347, 0. 305)   −2.04   0.088

The results of meta-regression analysis showed that sample types, ethnicity, and testing methods did not explore the potential sources of heterogeneity (coefficient = −1.521, P = 0.088; coefficient = −0.225, P = 0.845; coefficient = 2.835, P = 0.096, respectively).

A sensitivity analysis was also conducted to evaluate the stability of the overall OR and the change of heterogeneity by deleting a single study. When a study from Hoque 2004 et al. (\[[@R21]\], urine) was removed, the pooled OR was not significantly changed (OR = 2.06, 95% CI = 1.41-3.02), with no obvious heterogeneity (I^2^ = 23.2%, and P = 0.237).

Relation of *p16^INK4A^* and *p14^ARF^ promoter* methylation and clinicopathological features {#s2_5}
---------------------------------------------------------------------------------------------

We further determined whether *p16^INK4A^* and *p14^ARF^* promoter methylation status was associated with clinicopathological characteristics, such as sex, tumor grade, tumor stage, tumor size, lymph node status, and tumor histology. The fixed-effects model was used in relation to clinicopathological characteristics in cancer (all p \> 0.1) (Table [4](#T4){ref-type="table"}).

###### The pooled OR of *p16^INK4A^* and *p14^ARF^* promoter methylation with clinicopathological features in RCC

  Gene         Studies   Overall OR (95 CI %)   I^2^; P        P value   M (n)   RCCsmale   M (n)   RCCsfemale   P (Egger test)
  ------------ --------- ---------------------- -------------- --------- ------- ---------- ------- ------------ ----------------
  *p14ARF*     3         0.48 (0.25 - 0.94)     29.1%; 0.238   0.032     41      168        25      76           0.769
  *p16INK4A*   4         0.66 (0.31 - 1.38)     2.5%; 0.392    0.266     20      201        13      91           0.715
                                                                                 Grade1-2           Grade 3-4    
  *p14ARF*     3         2.13 (0.96 - 4.75)     17.5%; 0.297   0.063     40      111        15      72           0.613
  *p16INK4A*   7         1.20 (0.58 - 2.45)     0.0%; 0.620    0.625     41      212        13      102          0.644
                                                                                 Stage1-2           Stage 3-4    
  *p14ARF*     1         1.03 (0.18 - 5.98)     NA; NA         0.97      6       35         2       12           NA
  *p16INK4A*   4         1.00 (0.42 - 2.36)     0.0%; 0.786    0.999     25      104        11      52           0.211
                                                                                 pT2-4              pT1          
  *p14ARF*     4         0.92 (0.44 - 1.91)     7.4%; 0.356    0.815     16      94         41      180          0.229
  *p16INK4A*   6         2.43 (1.10 - 5.35)     0.0%; 0.615    0.028     28      132        12      203          0.36
                                                                                 Node+              Node-        
  *p14ARF*     2         0.35 (0.04 - 2.83)     0.0%; 0.665    0.326     0       11         23      123          NA
  *p16INK4A*   5         0.69 (0.18 - 2.69)     0.0%; 0.465    0.595     1       18         43      225          0.02
                                                                                 CCRCC              Non-CCRCC    
  *p14ARF*     4         0.38 (0.18 - 0.81)     0.0%; 0.607    0.012     34      185        25      100          0.294
  *p16INK4A*   7         0.54 (0.29 - 1.00)     0.0%; 0.842    0.051     53      289        31      144          0.015

M: methylation; ccRCC: clear cell renal cell carcinoma; NA: not applicable; Node+: lymph node-positive status; Node-: lymph node-negative status; RCC: renal cancer carcinoma; pT: pathological T category of primary tumor; n: the number of samples; OR: odds ratio; 95% confidence interval (95% CI).

Association of *p16^INK4A^* and *p14^ARF^* methylation and gender in cancer {#s2_6}
---------------------------------------------------------------------------

The pooled OR from four studies suggested that *p16^INK4A^* promoter methylation was not significantly correlated with gender in RCC (OR = 0.66, 95% CI = 0.31-1.38, P = 0.266), including in 201 males and 91 females (Table [4](#T4){ref-type="table"}). The pooled OR from three studies involving 168 males and 76 females suggested that *p14^ARF^* promoter methylation was significantly correlated with gender in RCC (OR = 0.48, 95% CI = 0.25-0.94, P = 0.032) (Table [4](#T4){ref-type="table"}), indicating that it was lower in males than in females.

Association of *p16^INK4A^* and *p14^ARF^* methylation and tumor grade in cancer {#s2_7}
--------------------------------------------------------------------------------

The pooled OR from seven studies and from three studies suggested that *p16^INK4A^* and *p14^ARF^* promoter methylation was not significantly correlated with tumor grade in RCC (OR = 1.20, 95% CI = 0.58-2.45, P = 0.625; OR = 2.13, 95% CI = 0.96-4.75, P = 0.063, respectively) (Table [4](#T4){ref-type="table"}).

Association of *p16^INK4A^* and *p14^ARF^* methylation and tumor stage in cancer {#s2_8}
--------------------------------------------------------------------------------

The pooled OR from four studies and from one study showed that *p16^INK4A^* and *p14^ARF^* promoter methylation was not significantly associated with tumor stage in RCC (OR = 1.00, 95% CI = 0.42-2.36, P = 0.999; OR = 1.03, 95% CI = 0.18-5.98, P = 0.97, respectively) (Table [4](#T4){ref-type="table"}).

Association of *p16^INK4A^* and *p14^ARF^* methylation and the pathological T category of primary tumor (pT) in cancer {#s2_9}
----------------------------------------------------------------------------------------------------------------------

The pooled OR from six studies including 132 pT2-4 patients and 203 pT1 patients suggested that *p16^INK4A^* promoter methylation was significantly correlated with tumor size in RCC (OR = 2.43, 95% CI = 1.10-5.35, P = 0.028) (Table [4](#T4){ref-type="table"}), indicating that it was higher in pT2-4 than in pT1. The pooled OR from four studies suggested that *p14^ARF^* promoter methylation was not significantly correlated with tumor size in RCC (OR = 0.92, 95% CI = 0.44-1.91, P = 0.815), including 94 pT2-4 patients and 180 pT1 patients (Table [4](#T4){ref-type="table"}).

Association of *p16^INK4A^* and *p14^ARF^* methylation and lymph node status in cancer {#s2_10}
--------------------------------------------------------------------------------------

The pooled OR from five studies and two studies showed that *p16^INK4A^* and *p14^ARF^* promoter methylation was not significantly associated with lymph node status in RCC (OR = 0.69, 95% CI = 0.18-2.69, P = 0.595; OR = 0.35, 95% CI = 0.04-2.83, P = 0.326, respectively) (Table [4](#T4){ref-type="table"}).

Association of *p16^INK4A^* and *p14^ARF^* methylation and tumor histology in cancer {#s2_11}
------------------------------------------------------------------------------------

The pooled OR from seven studies comprising 289 ccRCC and 144 non-ccRCC patients suggested that *p16^INK4A^* promoter methylation was not significantly associated with tumor histology in RCC (OR = 0.54, 95% CI = 0.29-1.00, P = 0.051) (Table [4](#T4){ref-type="table"}). The pooled OR from four studies involving 185 ccRCC and 100 non-ccRCC patients demonstrated that *p14^ARF^* promoter methylation was significantly correlated with tumor histology in RCC (OR = 0.38, 95% CI = 0.18-0.81, P = 0.012) (Table [4](#T4){ref-type="table"}), suggesting that it was lower in ccRCC than in non-ccRCC.

Prognostic value of *p16^INK4A^* and *p14^ARF^* gene promoter methylation in RCC {#s2_12}
--------------------------------------------------------------------------------

The detailed overall survival (OS), and disease-free survival (DFS) data on *p16^INK4A^* or *p14^ARF^* gene promoter methylation as a prognostic factor for RCC were insufficient. The mean follow-up time for the participants ranged from 28 months \[[@R22]\] to 76 months \[[@R23]\] in this meta-analysis. Dulaimi et al. 2004 \[[@R25]\], Vidaurreta et al. 2008 \[[@R23]\], and Martino et al. 2012 \[[@R22]\] reported that *p16^INK4A^* methylation was not significantly associated with the prognosis in DFS or OS (Table [1](#T1){ref-type="table"}). Dulaimi et al. 2004 \[[@R25]\] reported that *p14^ARF^* methylation was not significantly associated with the prognosis in OS (Table [1](#T1){ref-type="table"}). More studies with sufficient data are necessary to further evaluate the prognostic value of *p16^INK4A^* and *p14^ARF^* promoter methylation in RCC.

Publication bias {#s2_13}
----------------

The Egger test was used to evaluate potential publication bias. The Egger test showed low publication bias for *p16^INK4A^* promoter methylation in cancer patients versus control patients, and in cancer in relation to lymph node status and tumor histology (P = 0.011, P = 0.02, P = 0.015, respectively) (Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}).

DISCUSSION {#s3}
==========

The *p16^INK4A^* is formed from an alternative transcript of exons 1α, 2, and 3, whereas *p14^ARF^* is translated from alternative reading frames (ARF) consisting of exons 1β, 2, and 3 \[[@R32]\]. The silencing of *p16^INK4A^* and *p14^ARF^* can result in uncontrollable cell proliferation and tumor growth \[[@R32], [@R33]\]. Methylated *p16^INK4A^* and *p14^ARF^* have been investigated in various cancers, including RCC \[[@R18]\], esophageal squamous cell carcinoma \[[@R34]\], melanoma \[[@R35], [@R36]\], and gliomas \[[@R37]\]. Although numerous studies have been conducted to evaluate the role of *p16^INK4A^* and *p14^ARF^* promoter methylation in RCC, the results are still inconsistent and controversial. Kasahara et al. \[[@R38]\] found that the frequency of the methylated *p14^ARF^* was 0% in RCC. Hori et al. \[[@R20]\] found that the frequency of the methylated *p14^ARF^* was 70.5% in RCC. Morris et al. \[[@R27]\] reported that the frequency of *p16^INK4A^* promoter methylation was 0% in RCC. Arai et al. \[[@R24]\] reported that the frequency of *p16^INK4A^* promoter methylation was 73.3% in RCC. Therefore, we conducted this study of all available articles to further evaluate the effects of *p16^INK4A^* and *p14^ARF^* promoter methylation in RCC.

Analysis of the pooled OR showed that *p16^INK4A^* and *p14^ARF^* promoter methylation were significantly higher in patients with RCC than in control subjects, suggesting that *p16^INK4A^* and *p14^ARF^* inactivation via promoter methylation may play an important role in the tumorigenesis of RCC. Interestingly, *p14^ARF^* promoter methylation had a higher OR value (OR = 11.73) than that of *p16^INK4A^* promoter methylation (OR = 2.77) in cancer patients versus control patients, suggesting that RCC can be more susceptible to *p14^ARF^* promoter methylation.

When RCCs were compared to nonmalignant samples, the heterogeneity of *p16^INK4A^* promoter methylation was high (I^2^ = 51.7%, P = 0.029). According to sample type (tissue, serum, or urine), ethnicity (Caucasian or Asian), and testing method (MSP and non-MSP), subgroup analyses and meta-regression were used to explore the possible sources of heterogeneity. Analysis showed that subgroup analyses and meta-regression failed to find heterogeneity. Moreover, based on subgroup analyses of sample types, a significant association was observed between *p16^INK4A^* promoter methylation and tissue subgroup, but not in the serum and urine subgroups. The results should be carefully considered as only one study or two studies with a small number of samples involved in subgroup analyses. A sensitivity analysis was also performed in our study; when we deleted a study (Hoque 2004 et al., urine) \[[@R21]\], the overall OR was not significantly changed, with no significant heterogeneity, suggesting that our result was stable and reliable.

We further determined whether *p16^INK4A^* and *p14^ARF^* promoter methylation were correlated with clinicopathological features. Methylated *p14^ARF^* was significantly associated with gender, in which it was lower in males than in females, suggesting that female RCC patients can be more susceptible to *p14^ARF^* promoter methylation, whereas methylated *p16^INK4A^* had a similar frequency in males and females. Methylated *p16^INK4A^* was significantly associated with tumor size, in which it was higher in pT2-4 patients than in pT1 patients, suggesting that *p16^INK4A^* promoter methylation may play a key role in the pathogenesis of T2-4, whereas methylated *p14^ARF^* was not significantly correlated with tumor size. Methylated *p14^ARF^* was significantly associated with tumor histology, and it was lower in ccRCC than in non-ccRCC, suggesting that *p14^ARF^* promoter methylation had a decreased risk of ccRCC; whereas methylated *p16^INK4A^* had a similar frequency in ccRCC and Non-ccRCC. In addition, our findings showed that *p16^INK4A^* and *p14^ARF^* promoter methylation were not significantly associated with tumor grade, tumor stage, and lymph node status.

The prognostic data involving the pooled hazard ratio (HR) were insufficient and not available, as only three studies reporting showed that *p16^INK4A^* and *p14^ARF^* gene promoter methylation were not significantly correlated with the prognosis of RCC in OS or DFS \[[@R22], [@R23], [@R25]\]. More studies with sufficient data need to be done in the future.

The current study had several potential limitations. First, analysis of *p16^INK4A^* promoter methylation showed a slight publication bias in cancer versus control, and in cancer in relation to lymph node status and tumor histology. The articles with positive results are more often published than articles with negative results. The study was restricted to literatures published in English, which can lead to bias. In addition, because fluid samples from serum, plasma, and urine were limited, additional studies will be essential to evaluate the value of fluid detection in the future. Finally, the primary ethnic groups were Asian and Caucasian; thus, further studies using a larger variety of ethnic groups are warranted.

In conclusion, our study showed that RCC had a higher *p16^INK4A^* and *p14^ARF^* gene promoter methylation than did nonmalignant control patients. RCC had a higher *p16^INK4A^* promoter methylation in pT2-4 than in pT1. However, RCC had a lower *p14^ARF^* promoter methylation in males than in females, and was also lower in ccRCC than in non-ccRCC. Further large-scale studies with well-designed research are necessary to validate the role of *p16^INK4A^* and *p14^ARF^* promoter methylation in the prognosis and clinical effects of RCC patients in the future.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

This meta-analysis was conducted based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement criteria \[[@R39]\] ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). We systematically searched for the relevant literature in the PubMed, EMBASE, EBSCO, and Cochrane Library databases without language restrictions. We used the following free text and their combinations: (kidney OR renal) AND (cancer OR tumor OR neoplasm OR carcinoma) AND (CDKN2A OR MTS1 OR P16 OR INK4A OR P14 OR ARF) AND (methylation OR epigene\*) up to September 20, 2016. Finally, only full-text papers published in English were included in this study.

Inclusion criteria {#s4_2}
------------------

Eligible studies were selected in this meta-analysis if they met the following criteria: 1) patients were diagnosed with primary RCC; 2) although tissue specimens used must include surgically resected primary tumor samples, other samples, such as serum, plasm and urine, were used; 3) *CDKN2A* methylation included *p16^INK4A^* and *p14^ARF^* promoter methylation; 4) studies with sufficient data on *p16^INK4A^* and *p14^ARF^* promoter methylation frequency were selected to assess the association between *p16^INK4A^* and *p14^ARF^* promoter methylation and RCC; 5) to avoid duplicated publications, only the most recent paper or the most complete paper was included in the current study.

Data extraction {#s4_3}
---------------

We collected information from each eligible report regarding first author\'s name, country, ethnicity, testing method, sample type, methylation frequency, the number of samples, gender, tumor grade, clinical staging, pT, lymph node status, tumor histology, OS, and DFS. The whole data extraction was conducted independently by two authors, and minor disparities were solved by discussion.

Data analyses {#s4_4}
-------------

All statistical analyses were performed using STATA software (version 12.0, Stata Corporation, College Station, TX, USA). The pooled OR and 95 % confidence interval were calculated to assess the strength of the association between *p16^INK4A^* and *p14^ARF^* genes promoter methylation and RCC. Heterogeneity among studies was examined by Cochran test and the I^2^ test \[[@R40]\]. If I^2^ greater than 50% or p value less than 0.1 was considered as a measure of significant heterogeneity, then the random-effects model was applied in this study; otherwise, the fixed-effects model was used \[[@R41], [@R42]\]. The meta-regression and subgroup analyses were conducted to explore the source of heterogeneity. A sensitivity analysis was also performed to assess the contributions of an individual study on the overall OR by omitting one study \[[@R43]\]. Any possible publication bias was detected using the Egger linear regression test \[[@R44]\].
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